Search This Blog

Thursday, September 26, 2019

FDA OKs Endo’s generic Syprine

The FDA has approved Endo International (ENDP -6.2%) unit Par Pharmaceuticals’ Trientine Hydrochloride, a generic version of Bausch Health Companies’ (BHC +0.7%) Wilson’s disease med Syprine.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)